At the news
? BULLISHIMPACT 7/10 8-K filed Apr 9, 2026 at 08:01 ET
Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer based on interim data from the DENALI Part 2a trial. The company also announced an expanded trial design (Part 2c) and expects to complete enrollment and provide a topline readout by year-end 2026. The company maintains its cash runway into late 2027.
- Selected 400mg QD 5:2 as optimal dose for azenosertib based on interim data from DENALI Part 2a
- Demonstrated meaningful and clearly differentiated response rate at 400mg vs 300mg dose
- Observed comparable safety profiles between dose groups with improved discontinuation rates
- Expanded DENALI trial to include Part 2c cohort for patients previously treated with taxane-containing regimens
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access